trifluridine has been researched along with ma-1 in 103 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 18 (17.48) | 24.3611 |
| 2020's | 85 (82.52) | 2.80 |
| Authors | Studies |
|---|---|
| Bando, H; Doi, T; Fuse, N; Goto, K; Ito, Y; Kojima, T; Mukai, H; Naito, Y; Ohtsu, A; Yamazaki, T; Yoshino, T | 1 |
| Falcone, A; Salvatore, L | 1 |
| Aoyama, T; Hama, T; Inoue, A; Kawakami, K; Machida, Y; Suenaga, M; Sugisaki, T; Sugita, K; Suzuki, K; Takiguchi, T; Yamaguchi, K; Yamaguchi, T; Yokokawa, T | 1 |
| Burness, CB; Duggan, ST | 1 |
| Matsuoka, K; Nakagawa, F; Suzuki, N; Takechi, T | 1 |
| Imai, H; Matsuhashi, N; Matsui, S; Takahashi, T; Takano, J; Tanahashi, T; Tanaka, Y; Yamaguchi, K; Yoshida, K | 1 |
| Argilés, G; Élez, ME; Martini, G; Matos, I; Mulet, N; Noguerido, A; Tabernero, J | 1 |
| Bonetti, A; Giuliani, J | 3 |
| Li, J | 1 |
| Horiguchi, M; Sun, R; Wei, LJ | 1 |
| Addeo, A; Di Nardo, P | 1 |
| Matsuo, K; Matsuoka, K; Nakagawa, F; Okabe, H; Takechi, T; Tanaka, N | 1 |
| Nienhüser, H; Schmidt, T | 1 |
| Fuchs, M; Karthaus, M; Kasper, S; Kisro, J; Müller, C; Rafiyan, MR; Schulz-Abelius, A; Stein, A | 1 |
| Gourzoulidis, G; Kourlaba, G; Maniadakis, N; Pentheroudakis, G; Petrakis, D; Souglakos, J | 1 |
| Fu, H; Kim, DH; McCaw, ZR; Tian, L; Wei, LJ | 1 |
| Aria, AB; Chen, L; Chon, SY; Glass, WF; Lahoti, A | 1 |
| Banchi, M; Bocci, G; Cremolini, C; Cucchiara, F; Di Desidero, T; Falcone, A; Gentile, D; Moretto, R; Orlandi, P | 1 |
| Barghout, V; Duh, MS; Germain, G; Jacques, P; Laliberté, F; Patel, AK; Yenikomshian, MA | 1 |
| Alsina, M; Arkenau, HT; Beretta, GD; Catenacci, D; Doi, T; Fujitani, K; George, B; Ghidini, M; Ilson, DH; Makris, L; Mansoor, W; McGuigan, S; Prokharau, A; Shitara, K; Tabernero, J; Thuss-Patience, P; Van Cutsem, E; Zhavrid, E | 1 |
| Asai, A; Doki, Y; Haraguchi, N; Ishii, H; Kobunai, T; Konno, M; Koseki, J; Matsuoka, K; Mori, M; Takechi, T; Tsunekuni, K | 1 |
| Ahn, DH; Alberts, SR; Bekaii-Saab, TS; Borad, MJ; Chakrabarti, S; Durgin, LM; Fruth, B; Hartgers, ML; Liu, MC; Mahipal, A; McWilliams, RR; Ou, FS; Walkes, RL; Wessling, J; Zemla, TJ | 1 |
| Grothey, A; Kasi, PM | 1 |
| Argilés, G; Baba, H; Benedetti, F; Cleary, JM; Esaki, T; Falcone, A; Garcia-Carbonero, R; Hamada, C; Hochster, HS; Komatsu, Y; Lenz, HJ; Makris, L; Mayer, RJ; Moriwaki, T; Muro, K; Nishina, T; Ohtsu, A; Peeters, M; Shimada, Y; Shinozaki, E; Sobrero, A; Sugimoto, N; Tanase, T; Tran, B; Tsuji, A; Tsuji, Y; Van Cutsem, E; Yamaguchi, K; Yamashita, F; Yamazaki, K; Yoshino, T; Zaniboni, A | 1 |
| Alsina, M; Amellal, N; Ando, T; Arkenau, HT; Doi, T; Dvorkin, M; Faustino, C; Ghidini, M; Gorbunova, V; Ilson, DH; Leger, C; Mansoor, W; Nishikawa, K; Prokharau, A; Sabater, J; Shitara, K; Skanji, D; Tabernero, J; Van Cutsem, E; Yalçın, Ş; Zhavrid, E | 1 |
| Colloca, G; Guarneri, D; Venturino, A | 1 |
| Lenz, HJ; Yoshino, T | 1 |
| Atlan, D; Bachet, JB; Becquart, M; Cicin, I; Cremolini, C; Falcone, A; Mounedji, N; Ozet, A; Phelip, JM; Portales, F; Price, T; Taieb, J; Van Cutsem, E; Vidot, L; Wyrwicz, L | 1 |
| Amellal, N; Argilés, G; Aubel, P; Borg, C; Danielewicz, I; Egorov, A; Falcone, A; Fedyanin, M; Garcia-Alfonso, P; Glynne-Jones, R; Kanehisa, A; Kroening, H; Moiseenko, V; Pfeiffer, P; Punt, CJA; Saunders, MP; Stroyakovskiy, D; Van Cutsem, E; Van de Wouw, AJ; Wasan, H | 1 |
| Cervantes, A; Huerta, M; Roda, D; Roselló, S | 1 |
| Kashiwa, M; Matsushita, R | 1 |
| Brochériou, I; Desbuissons, G; Fournier, P; Ngango, L | 1 |
| Argiles, G; Borg, C; Mayer, RJ; Moreno Vera, SR; Ohtsu, A; Sobrero, AF; Tabernero, J; Van Cutsem, E; Vidot, L | 1 |
| Lin, BR; Lin, YL; Liu, KL | 1 |
| Cheung, WY; Dolley, A; Kavan, P | 1 |
| Akagi, Y; Ando, K; Baba, H; Kabashima, A; Kashiwada, T; Kawanaka, H; Kotaka, M; Maehara, Y; Makiyama, A; Miwa, K; Miyamoto, Y; Mori, M; Noguchi, T; Oki, E; Saeki, H; Shimokawa, M; Yuge, K | 1 |
| Bonetti, A; Giuliani, J; Insolda, J; Pigozzi, E | 1 |
| Hamada, S; Ikeda, J; Komatsu, S; Konishi, T; Matsubara, D; Shibata, R; Shimomura, K; Shioaki, Y; Soga, K; Taniguchi, F | 1 |
| Sonbol, MB; Yoon, HH; Zhu, M | 1 |
| Arigami, T; Kita, Y; Kurahara, H; Maemura, K; Matsumoto, R; Mori, S; Natsugoe, S; Sasaki, K; Toda, H | 1 |
| Fukada, M; Futamura, M; Imai, H; Imai, T; Iwata, Y; Matsuhashi, N; Mori, R; Okumura, N; Sato, Y; Suetsugu, T; Takahashi, T; Tanaka, H; Tanaka, Y; Yasufuku, I; Yoshida, K | 1 |
| Asayama, M; Kagawa, Y; Maehara, Y; Makiyama, A; Manaka, D; Matsuhashi, N; Mitsugi, K; Nakamura, M; Oba, K; Ojima, H; Oki, E; Okuda, H; Shimada, Y; Shiozawa, M; Takahashi, T; Watanabe, J; Yamazaki, K; Yoshida, K; Yoshino, T; Yuasa, Y | 1 |
| Androulakis, N; Beletsi, A; Boukovinas, I; Chotzagiannoglou, V; Gourzoulidis, G; Karamouzis, M; Koulentaki, M; Koumarianou, A; Kourlaba, G; Papakotoulas, P; Samadas, E; Souglakos, J; Xynogalos, S | 1 |
| Denda, T; Gamoh, M; Goto, M; Iwata, M; Kagawa, Y; Kato, T; Komatsu, Y; Kotaka, M; Kuboki, Y; Makiyama, A; Oba, K; Oki, E; Satake, H; Shibuya, K; Soeda, J; Tanioka, H; Yamaguchi, K; Yamazaki, K; Yasui, H; Yoshino, T | 1 |
| Aleshin, A; Billings, PR; Ebi, H; Kato, T; Kotani, D; Mishima, S; Mori, M; Nakamura, Y; Oki, E; Rabinowitz, M; Sawada, K; Shirasu, H; Takemasa, I; Taniguchi, H; Yamanaka, T; Yoshino, T; Yukami, H | 1 |
| Ceribelli, A; Chilelli, MG; DE Marco, S; Gemma, D; Grande, R; Morandi, MG; Ruggeri, EM; Saltarelli, R; Signorelli, C; Sperduti, I; Spinelli, GP; Zoratto, F | 1 |
| Court, OR; Shemilt, K | 1 |
| Doi, T; Igarashi, A; Shitara, K; Takushima, Y; Yoshihara, H | 1 |
| Alsina, M; Arkenau, HT; Azcue, P; Catenacci, DVT; Doi, T; Fornaro, L; Fougeray, R; Ilson, DH; Lorenzen, S; Moreno, SR; Shitara, K; Tabernero, J; Van Cutsem, E; Zaanan, A | 1 |
| Essapen, S; Mendis, J; Tong, D; Wang, L | 1 |
| Abhyankar, R; Barghout, VE; Brais, LK; Duh, MS; Fuchs, CS; Huynh, L; Ng, K; Patel, AK; Yenikomshian, MA | 1 |
| Creemers, GJ; Deenen, MJ; Sanders, SJWJ; Schouten, JF; Willems, J | 1 |
| Abdel-Raouf, S; Angelis, V; Barry, A; Baxter, M; Chauhan, M; Eccles, B; Graham, JS; Hill, M; Holden, C; Iveson, T; Karampera, C; Khan, S; Martinou, M; Mills-Baldock, T; Pouptsis, A; Ross, PJ; Satterthwaite, L; Shiu, KK; Stavraka, C; Synowiec, A; Thomas, A; Young, S | 1 |
| En, W; Fukuoka, T; Hirakawa, K; Iseki, Y; Kashiwagi, S; Ohira, M; Okazaki, Y; Shibutani, M | 1 |
| Giuliani, J | 1 |
| Alsina, M; Benhadji, KA; Cicin, I; Doi, T; Hosaka, H; Ilson, DH; Longo, F; Makris, L; Özgüroğlu, M; Ozyilkan, O; Park, D; Pericay, C; Santoro, A; Shitara, K; Thuss-Patience, P; Zaanan, A | 1 |
| Hara, H; Hironaka, S; Horimatsu, T; Ishihara, R; Kasai, H; Kato, K; Kawaguchi, A; Kikuchi, O; Kojima, T; Mori, Y; Mukai, K; Muto, M; Tada, H; Tsushima, T; Uozumi, R | 1 |
| Arkenau, HT; Fostea, RM | 1 |
| Ettrich, TJ; Heinemann, V; Hess, J; Karthaus, M; Klein, A; Kretzschmar, A; Pelz, H; Reisländer, T; Riera-Knorrenschild, J; Vehling-Kaiser, U; Weiss, L; Welslau, M | 1 |
| Basto, R; Bonito, N; Gomes, I; Jacinto, P; Magalhães, J; Paulo, J; Pereira, TC; Sousa, G; Sousa, MJ | 1 |
| Artru, P; Bouché, O; Coriat, R; Coutzac, C; De La Fouchardière, C; Doat, S; Gallois, C; Henriques, J; Masson, T; Moulin, V; Saint, A; Taieb, J; Tougeron, D; Trouilloud, I; Vernerey, D | 1 |
| Dijksterhuis, WPM; Elferink, MAG; Hamers, PAH; Koopman, M; May, AM; Punt, CJA; Stellato, RK; Vink, GR | 1 |
| Boku, N; Hirano, H; Iwasa, S; Okita, N; Oshima, K; Shoji, H; Takashima, A | 1 |
| Amellal, N; Aubel, P; Cattan, V; Fougeray, R; Kim, TW; Li, J; Mayer, RJ; Ohtsu, A; Shen, L; Sriuranpong, V; Van Cutsem, E; Xuereb, L; Yoshino, T | 1 |
| Bonetti, A; Giuliani, J; Mantoan, B | 1 |
| Dechow, T; Ettrich, TJ; Fruehauf, S; Fuchs, M; Heinemann, V; Hoyer, I; Kaiser, F; Karthaus, M; Kiani, A; König, A; Kurreck, A; Modest, DP; Müller, L; Quante, M; Reinacher-Schick, A; Roderburg, C; Schwaner, I; Sommerhäuser, G; Stahler, A; Stintzing, S; von Weikersthal, LF | 1 |
| Chucla, TC; De Castro, BA; de la Cámara Gomez, J; Diaz, SS; Fernández, FB; Lopez, MR; Martínez-Lago, N; Ponte, RV; Rendo, CR; Rodriguez, MIG; Salvador, MM; Suarez, BG | 1 |
| Arrichiello, G; Ciardiello, D; Ciardiello, F; De Falco, V; Facchini, G; Famiglietti, V; Incoronato, P; Laterza, MM; Martinelli, E; Martini, G; Nacca, V; Napolitano, R; Napolitano, S; Nicastro, A; Paragliola, F; Perrone, A; Suarato, G; Troiani, T | 1 |
| Chen, YC; Dragovich, T; Jimeno, A; Kopetz, S; Kundranda, M; Lieu, C; Menter, D; Pant, S; Tchaparian, E | 1 |
| Arkenau, HT; Benhadji, KA; Doi, T; Falcone, A; George, B; Hochster, H; Ilson, DH; Makris, L; Mayer, R; Ohtsu, A; Shitara, K; Tabernero, J; Van Cutsem, E; Yoshino, T | 1 |
| Amellal, N; André, T; Aubel, P; Campos-Bragagnoli, A; Chmielowska, E; Csöszi, T; Falcone, A; Fougeray, R; Liposits, G; Martín, L; Moiseenko, F; Polo-Marques, E; Saunders, MP; Shparyk, Y | 1 |
| Chen, B; Chen, X; He, Y; Liu, Y; Lv, H; Nie, C; Wang, J; Wang, S; Xu, W; Zhao, J | 1 |
| Fujioka, A; Hayashi, H; Nagase, H; Nukatsuka, M; Tanaka, G | 1 |
| Cheung, WY; Ding, PQ; Dolley, A | 1 |
| Bachet, JB; Chevallier, B; Price, T; Taieb, J; Vidot, L; Wyrwicz, L | 1 |
| Ikoma, T; Matsumoto, T; Miura, K; Nagai, H; Takatani, M; Tsuduki, T; Watanabe, T; Yamamura, S; Yasui, H | 1 |
| Florou, V; Garrido-Laguna, I; Haaland, B; Nevala-Plagemann, C; Sama, S; Shen, J; Ying, J | 1 |
| Hara, H; Ishihara, S; Kagawa, Y; Kajiwara, T; Kawakami, H; Kotaka, M; Kuboki, Y; Makiyama, A; Masuishi, T; Morita, S; Nakajima, TE; Nakamura, M; Ojima, H; Oki, E; Ozawa, D; Shirao, K; Sugimoto, N; Sunakawa, Y; Takashima, A; Takenaka, N; Taniguchi, H; Terazawa, T; Watanabe, J; Yoshino, T | 1 |
| Aoyama, T; Furusawa, K; Furuta, M; Hamaguchi, T; Hashimoto, I; Hayashi, K; Inokuchi, Y; Kanematsu, K; Kano, K; Machida, N; Nagasawa, S; Ogata, T; Onuma, S; Oshima, T; Rino, Y; Suematsu, H; Watanabe, M; Yamada, T | 1 |
| Araujo, KB; Festa, J; Mardegan, L; Meton, F; Piranda, DN; Victorino, APOS | 1 |
| Fujii, H; Hirose, C; Iihara, H; Kiyama, S; Kobayashi, R; Makiyama, A; Matsuhashi, N; Matsuoka, S; Ohata, K; Sadaka, S; Suzuki, A; Takahashi, T; Watanabe, D | 1 |
| Amellal, N; Benhadji, KA; Bondarenko, I; Ciardiello, F; Cremolini, C; Cruz, FM; Elez, E; Fakih, M; Leger, C; Liposits, G; Modest, DP; Pápai, Z; Poureau, PG; Prager, GW; Stroyakovskiy, D; Tabernero, J; Taieb, J; Van Cutsem, E; Vidot, L; Wyrwicz, L | 1 |
| Altucci, L; Avallone, A; Bordonaro, R; Cardone, C; Ciardiello, D; Ciardiello, F; De Falco, V; De Stefano, A; De Vita, F; Della Corte, CM; Di Liello, A; Di Maio, M; Esposito, L; Famiglietti, V; Marrone, F; Martinelli, E; Martini, G; Montesarchio, V; Napolitano, S; Santini, D; Scartozzi, M; Troiani, T; Zampino, MG | 1 |
| Benhadji, KA; Fakih, MG; George, B; Ghidini, M; Makris, L; Shitara, K; Sundar, R; Taieb, J | 1 |
| Berres, ML; Gonzalez-Carmona, M; Kehmann, L; Keitel, V; Luedde, T; Modest, DP; Mohr, R; Roderburg, C; Strassburg, C; Trautwein, C; Venerito, M; Wree, A | 1 |
| Furusawa, K; Furuse, J; Furuta, M; Hamaguchi, T; Hashimoto, I; Hayashi, K; Inokuchi, Y; Kanematsu, K; Machida, N; Maeda, S; Nagasawa, S; Notsu, A; Ogata, T; Onuma, S; Oshima, T; Suematsu, H; Watanabe, M; Yamada, T | 1 |
| Bruch, HR; de Buhr, R; Decker, T; Frank, M; Göhler, T; Grundeis, M; Grunewald, R; Harich, HD; Hartmann, F; Hogrefe, C; Kojouharoff, G; Kröning, H; Liersch, R; Lipke, J; Marschner, N; Moorahrend, E; Nusch, A; Potthoff, K; Reisländer, T; Sauer, A; Schwaner, I; Semsek, D; Stephany, M; Uhlig, J; Vehling-Kaiser, U; Welslau, M | 1 |
| Ando, M; Hamauchi, S; Honda, K; Kadowaki, S; Kawakami, T; Masuishi, T; Mori, K; Muro, K; Narita, Y; Onozawa, Y; Shirasu, H; Taniguchi, H; Todaka, A; Tsushima, T; Yamazaki, K; Yasui, H; Yokota, T | 1 |
| Amor Urbano, M; Aviñó Tarazona, V; Bayo Calero, J; Domínguez Senín, L; Rodriguez Garcés, MY; Santos-Rubio, MD | 1 |
| Bebyn, M; Koper, A; Koper, K; Śledzińska, P; Wileński, S | 1 |
| Alberts, SR; Borad, MJ; Chakrabarti, S; Fernandez-Zapico, ME; Foster, N; Fruth, B; Hartgers, M; Hogenson, TL; Jin, Z; Mahipal, A; McWilliams, RR; Nguyen, T; Pitot, H; Qian, S; Tella, SH; Washburn, L; Wee Ma, W; Wessling, J | 1 |
| Voutsadakis, IA | 1 |
| Altucci, L; Avallone, A; Cardone, C; Ciardiello, D; Ciardiello, F; De Falco, V; De Stefano, A; De Vita, F; Del Tufo, S; Della Corte, CM; Di Liello, A; Di Maio, M; Esposito, L; Famiglietti, V; Fazio, N; Marrone, F; Martinelli, E; Martini, G; Montesarchio, V; Napolitano, S; Troiani, T; Zampino, MG | 1 |
| Valeri, N; van de Haar, J; Voest, EE | 1 |
| Fakih, M; Prager, GW; Tabernero, J | 1 |
| Andreozzi, V; Barros, AG; Brito-da-Silva, J; Costa, AL; Costa, L; Cruz, J; Dâmaso, S; Félix, J; Mansinho, A; Marques, D; Mota, M; Pinheiro, S; Pratas, E; Quintela, A; Rodrigues, J; Teixeira, AR | 1 |
| Boku, N; Hara, H; Hirata, K; Hironaka, S; Kawakami, H; Masuishi, T; Matsumoto, T; Muro, K; Nagashima, K; Takahashi, N; Yamazaki, K | 1 |
| Kagawa, Y; Kunitomi, Y; Nakashima, M; Okude, R; Shinozaki, E; Tone, T | 1 |
| Kawazoe, A; Kotani, D; Kuboki, Y; Mishima, S; Nakamura, H; Nakamura, Y; Okunaka, M; Shitara, K | 1 |
| Esaki, T; Fukuoka, S; Kajiwara, T; Kumekawa, Y; Makiyama, A; Masuishi, T; Moriwaki, T; Shimada, Y; Shiroyama, M; Takashima, A; Yamazaki, K | 1 |
6 review(s) available for trifluridine and ma-1
| Article | Year |
|---|---|
Trifluridine/Tipiracil: A Review in Metastatic Colorectal Cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Colorectal Neoplasms; Disease-Free Survival; Humans; Pyrrolidines; Thymine; Trifluridine | 2016 |
Trifluridine/tipiracil in the treatment of gastric cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Clinical Trials, Phase III as Topic; Drug Combinations; Humans; Pyrrolidines; Stomach Neoplasms; Thymine; Trifluridine | 2022 |
Effect of KRAS codon 12 or 13 mutations on survival with trifluridine/tipiracil in pretreated metastatic colorectal cancer: a meta-analysis.
Topics: Codon; Colonic Neoplasms; Colorectal Neoplasms; Frontotemporal Dementia; Humans; Mutation; Proto-Oncogene Proteins p21(ras); Pyrrolidines; Randomized Controlled Trials as Topic; Thymine; Trifluridine; Uracil | 2022 |
Trifluridine/tipiracil (FTD/TPI) and regorafenib in older patients with metastatic colorectal cancer.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Colonic Neoplasms; Colorectal Neoplasms; Frontotemporal Dementia; Humans; Rectal Neoplasms; Trifluridine; Uracil | 2023 |
Effect of 12-week of aerobic exercise on hormones and lipid profile status in adolescent girls with polycystic ovary syndrome: A study during COVID-19.
Topics: Actin Cytoskeleton; Actins; Adaptor Proteins, Signal Transducing; Adenocarcinoma; Adenosine Triphosphate; Adsorption; Adult; Africa, Eastern; Aged; Air Pollutants; Air Pollution; Air Pollution, Indoor; Alcohol Drinking; Allergens; Alzheimer Disease; Amyotrophic Lateral Sclerosis; Animals; Anti-Bacterial Agents; Antibodies; Antibodies, Immobilized; Antigen Presentation; Antigens, CD; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Antioxidants; Apoptosis; Aptamers, Nucleotide; Asthma; Asthma, Exercise-Induced; Atrophy; Autophagy; Azoospermia; Bacillus cereus; Bacterial Infections; Beclin-1; Bile Duct Neoplasms; Bile Ducts, Intrahepatic; Biofouling; Biological Monitoring; Biomarkers; Biomarkers, Tumor; Biosensing Techniques; Blastocyst; Bone Neoplasms; Bone Regeneration; Bronchoconstriction; Burkitt Lymphoma; C9orf72 Protein; Campylobacter; Campylobacter Infections; Campylobacter jejuni; Carcinogenesis; Carcinoma, Hepatocellular; Carcinoma, Pancreatic Ductal; Carcinoma, Squamous Cell; Cardiomyopathies; Caregivers; Carmine; Case-Control Studies; Catalysis; Cattle; Cause of Death; CCAAT-Enhancer-Binding Protein-alpha; CD8-Positive T-Lymphocytes; Cefepime; Cell Differentiation; Cell Line, Tumor; Cell Nucleus; Cell Transdifferentiation; Chelating Agents; Chemical and Drug Induced Liver Injury, Chronic; Chemoradiotherapy, Adjuvant; Child; Child, Preschool; China; Chlorquinaldol; Cholangiocarcinoma; Cholera; Chromatin; Clinical Trials as Topic; Cognitive Dysfunction; Cohort Studies; Colonic Neoplasms; Colorectal Neoplasms; Colorimetry; Cooking; Coordination Complexes; COVID-19; Creatinine; CRISPR-Cas Systems; Critical Care; Critical Illness; Cross-Sectional Studies; Cryopreservation; Cryoprotective Agents; Cysteine; Cytokines; Device Removal; Diet; Diet, High-Fat; Diet, Mediterranean; Dietary Supplements; Dimethyl Sulfoxide; Dipeptides; Disease Models, Animal; Dithiothreitol; DNA; DNA Repeat Expansion; DNA, Bacterial; DNA, Complementary; Dopamine; Electrochemical Techniques; Electrodes; Endocannabinoids; Environmental Exposure; Environmental Monitoring; Environmental Pollutants; Enzyme-Linked Immunosorbent Assay; Erlotinib Hydrochloride; Escherichia coli; Escherichia coli O157; Esophageal Neoplasms; Esophagitis, Peptic; Ethylene Glycol; Europium; Exanthema; Fallopian Tubes; Feces; Female; Fertilization in Vitro; Fluoresceins; Fluorescent Dyes; Follicle Stimulating Hormone; Follow-Up Studies; Food Microbiology; Forced Expiratory Volume; Forkhead Transcription Factors; Frontotemporal Dementia; G-Quadruplexes; Galactose; Gastroenteritis; Gastrointestinal Diseases; Gastrointestinal Microbiome; Gastrointestinal Neoplasms; Gastrointestinal Tract; Gene Frequency; Genetic Association Studies; Genetic Predisposition to Disease; Genital Neoplasms, Female; Genome-Wide Association Study; Genome, Viral; Genomics; Genotype; Glucose; Glutathione; Glycerol; Gold; Graphite; GTPase-Activating Proteins; Heat-Shock Proteins; Heme Oxygenase-1; Hepacivirus; Hepatitis C; Hepatocytes; Histamine; Histocompatibility Antigens Class II; Hoarseness; Hospice and Palliative Care Nursing; Humans; Hydrogen; Hydrogen Peroxide; Hydrogen Sulfide; Hydroxybenzoates; Hydroxyl Radical; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperthermia, Induced; Hysteroscopy; Immunoassay; Indigo Carmine; Inflammation; Inflammatory Bowel Diseases; Insulin Resistance; Intensive Care Units; Interleukin-11; Interleukin-6; Interleukins; Iodine Radioisotopes; Iran; Iridium; Islets of Langerhans; Kinetics; Lactation; Lactobacillus; Lactobacillus plantarum; Lamins; Latin America; Lead; Lectins; Leukopenia; Ligands; Limit of Detection; Lipopolysaccharides; Lipoprotein Lipase; Liver; Liver Cirrhosis; Liver Neoplasms; Lolium; Luminescent Measurements; Luminol; Lung; Luteinizing Hormone; Macrophages; Magnetic Phenomena; Magnetic Resonance Imaging; Male; Malnutrition; Maltose; Manganese Compounds; Maternal Nutritional Physiological Phenomena; Melatonin; Metabolic Engineering; Metal Nanoparticles; Metallocenes; Metaplasia; Methicillin-Resistant Staphylococcus aureus; Methylation; Mevalonic Acid; Mexico; Mice; Mice, Inbred C57BL; Mice, Transgenic; Microbial Sensitivity Tests; Microbiota; MicroRNAs; Milk; Mitomycin; Molecular Diagnostic Techniques; Molecular Docking Simulation; Monte Carlo Method; Moringa oleifera; Multiple Sclerosis; Muscle Strength; Muscle, Skeletal; Nanocomposites; Nanotubes, Carbon; Neoadjuvant Therapy; Neoplasms; Neurodegenerative Diseases; Neurotransmitter Agents; NF-E2-Related Factor 2; Nickel; Nitrogen Dioxide; Non-alcoholic Fatty Liver Disease; Nucleic Acid Amplification Techniques; Nucleic Acid Hybridization; Nucleocapsid Proteins; Nutritional Status; Obesity; Osteogenesis; Osteosarcoma; Oxidation-Reduction; Oxides; Oxygen; Oxyquinoline; Pain; Palliative Care; Pancreatic Neoplasms; Pandemics; Particulate Matter; Peroxidase; Peroxidases; Phagocytosis; Phaseolus; Photothermal Therapy; Point-of-Care Systems; Polyethyleneimine; Polymers; Polymorphism, Single Nucleotide; Polysomnography; Postoperative Complications; Pregnancy; Pregnant Women; Prenatal Exposure Delayed Effects; Prevalence; Printing, Three-Dimensional; Probability; Probiotics; Prognosis; Prophages; Prospective Studies; Proteomics; Proto-Oncogene Proteins; Pseudomonas aeruginosa; Pseudomonas putida; Pulmonary Disease, Chronic Obstructive; Pulmonary Embolism; Pyridines; Pyrroles; Quality of Life; Quinolones; Rabbits; Rats; Rats, Sprague-Dawley; Reactive Oxygen Species; Real-Time Polymerase Chain Reaction; Receptors, Histamine; Receptors, Histamine H2; Recombinases; Rectal Neoplasms; Reperfusion Injury; Respiration; Respiratory Function Tests; Respiratory Rate; Respiratory Sounds; Retrospective Studies; rho GTP-Binding Proteins; Risk Assessment; Risk Factors; RNA; RNA, Messenger; RNA, Ribosomal, 16S; Robotic Surgical Procedures; Running; Rural Population; Saccharomyces cerevisiae; Salpingectomy; Sarcopenia; SARS-CoV-2; Seeds; Semen; Sensitivity and Specificity; Sepsis; Shock, Septic; Signal Transduction; Silicon Dioxide; Silver; Sirtuin 1; Skin Neoplasms; Sleep Apnea, Obstructive; Soil; Spain; Spectrum Analysis, Raman; Sperm Retrieval; Spermatozoa; Spirometry; Staphylococcus aureus; STAT3 Transcription Factor; Stereoisomerism; Sterilization, Tubal; Stroke Volume; Sulfadiazine; Sulfites; Superoxide Dismutase; Surface Plasmon Resonance; tau Proteins; Testis; Testosterone; Thioredoxin-Disulfide Reductase; Thyroid Neoplasms; Thyroidectomy; Trans-Activators; Transcription Factor AP-1; Treatment Outcome; Triazoles; Triclosan; Trifluridine; Tumor Microenvironment; Tumor Necrosis Factor-alpha; United States; Uracil; Vagina; Vegetables; Ventricular Function, Left; Ventricular Pressure; Vibrio cholerae; Vietnam; Virulence; Vital Capacity; Vitrification; Walking; Water; Water Pollutants, Radioactive; Whole Genome Sequencing; Wind; YAP-Signaling Proteins; Zeolites; Zinc Oxide | 2023 |
A Systematic Review and Meta-Analysis of Trifluridine/Tipiracil plus Bevacizumab for the Treatment of Metastatic Colorectal Cancer: Evidence from Real-World Series.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Colonic Neoplasms; Colorectal Neoplasms; Humans; Rectal Neoplasms; Trifluridine; Uracil | 2023 |
31 trial(s) available for trifluridine and ma-1
| Article | Year |
|---|---|
Effect of food on the pharmacokinetics of TAS-102 and its efficacy and safety in patients with advanced solid tumors.
Topics: Aged; Anemia; Antineoplastic Agents; Area Under Curve; Asian People; Biological Availability; Cross-Over Studies; Drug Combinations; Fasting; Female; Food-Drug Interactions; Humans; Japan; Leukopenia; Male; Middle Aged; Nausea; Neoplasms; Neutropenia; Pyrrolidines; Thymine; Trifluridine; Uracil | 2016 |
Efficacy and Safety of Trifluridine/Tipiracil Treatment in Patients With Metastatic Gastric Cancer Who Had Undergone Gastrectomy: Subgroup Analyses of a Randomized Clinical Trial.
Topics: Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Drug Combinations; Gastrectomy; Humans; Male; Middle Aged; Pyrrolidines; Stomach Neoplasms; Thymine; Trifluridine | 2020 |
Phase II Trial of Trifluridine/Tipiracil in Patients with Advanced, Refractory Biliary Tract Carcinoma.
Topics: Biliary Tract; Carcinoma; Humans; Pyrrolidines; Thymine; Trifluridine; Uracil | 2020 |
Neutropenia and survival outcomes in metastatic colorectal cancer patients treated with trifluridine/tipiracil in the RECOURSE and J003 trials.
Topics: Colorectal Neoplasms; Drug Combinations; Humans; Japan; Neutropenia; Pyrrolidines; Thymine; Trifluridine; Uracil | 2020 |
Health-related quality of life associated with trifluridine/tipiracil in heavily pretreated metastatic gastric cancer: results from TAGS.
Topics: Adenocarcinoma; Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Double-Blind Method; Female; Follow-Up Studies; Humans; International Agencies; Male; Middle Aged; Prognosis; Pyrrolidines; Quality of Life; Stomach Neoplasms; Survival Rate; Thymine; Trifluridine; Young Adult | 2020 |
Safety, efficacy and patient-reported outcomes with trifluridine/tipiracil in pretreated metastatic colorectal cancer: results of the PRECONNECT study.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Female; Humans; Male; Middle Aged; Patient Reported Outcome Measures; Pyrrolidines; Quality of Life; Thymine; Trifluridine; Vascular Endothelial Growth Factor A | 2020 |
Trifluridine/tipiracil plus bevacizumab in patients with untreated metastatic colorectal cancer ineligible for intensive therapy: the randomized TASCO1 study.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Capecitabine; Colorectal Neoplasms; Fluorouracil; Humans; Pyrrolidines; Quality of Life; Thymine; Trifluridine | 2020 |
Comparative Cost-utility Analysis of Regorafenib and Trifluridine/Tipiracil in The Treatment of Metastatic Colorectal Cancer in Japan.
Topics: Adult; Colorectal Neoplasms; Cost-Benefit Analysis; Drug Combinations; Humans; Japan; Phenylurea Compounds; Pyridines; Pyrrolidines; Quality-Adjusted Life Years; Thymine; Trifluridine | 2020 |
Effect of trifluridine/tipiracil in patients treated in RECOURSE by prognostic factors at baseline: an exploratory analysis.
Topics: Colorectal Neoplasms; Drug Combinations; Female; Humans; Male; Middle Aged; Prognosis; Pyrrolidines; Quality of Life; Thymine; Trifluridine | 2020 |
Trifluridine/tipiracil plus bevacizumab as a first-line treatment for elderly patients with metastatic colorectal cancer (KSCC1602): A multicenter phase II trial.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Colorectal Neoplasms; Female; Follow-Up Studies; Humans; Male; Prognosis; Pyrrolidines; Survival Rate; Thymine; Trifluridine | 2021 |
Phase II study of trifluridine/tipiracil plus bevacizumab by RAS mutation status in patients with metastatic colorectal cancer refractory to standard therapies: JFMC51-1702-C7.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Colorectal Neoplasms; Humans; Mutation; Pyrrolidines; Thymine; Trifluridine | 2021 |
Safety and efficacy of panitumumab in combination with trifluridine/tipiracil for pre-treated patients with unresectable, metastatic colorectal cancer with wild-type RAS: The phase 1/2 APOLLON study.
Topics: Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Humans; Panitumumab; Pyrrolidines; Thymine; Trifluridine | 2021 |
CIRCULATE-Japan: Circulating tumor DNA-guided adaptive platform trials to refine adjuvant therapy for colorectal cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Chemotherapy, Adjuvant; Circulating Tumor DNA; Colonic Neoplasms; Colorectal Neoplasms; Double-Blind Method; Humans; Japan; Neoplasm Recurrence, Local; Oxaliplatin; Prospective Studies; Pyrrolidines; Thymine; Trifluridine | 2021 |
Efficacy and safety of trifluridine/tipiracil in older and younger patients with metastatic gastric or gastroesophageal junction cancer: subgroup analysis of a randomized phase 3 study (TAGS).
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Drug Combinations; Esophageal Neoplasms; Esophagogastric Junction; Frontotemporal Dementia; Humans; Pyrrolidines; Stomach Neoplasms; Thymine; Trifluridine | 2022 |
Multicenter phase II study of trifluridine/tipiracil for esophageal squamous carcinoma refractory/intolerant to 5-fluorouracil, platinum compounds, and taxanes: the ECTAS study.
Topics: Esophageal Neoplasms; Esophageal Squamous Cell Carcinoma; Fluorouracil; Humans; Japan; Neoplasm Recurrence, Local; Platinum Compounds; Pyrrolidines; Taxoids; Trifluridine | 2022 |
Efficacy, safety and quality-of-life data from patients with pre-treated metastatic colorectal cancer receiving trifluridine/tipiracil: results of the TALLISUR trial.
Topics: Colorectal Neoplasms; Humans; Prospective Studies; Pyrrolidines; Quality of Life; Thymine; Trifluridine | 2022 |
Study protocol of the FIRE-8 (AIO-KRK/YMO-0519) trial: a prospective, randomized, open-label, multicenter phase II trial investigating the efficacy of trifluridine/tipiracil plus panitumumab versus trifluridine/tipiracil plus bevacizumab as first-line tre
Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Body Weight; Clinical Trials, Phase II as Topic; Colorectal Neoplasms; Fluorouracil; Humans; Multicenter Studies as Topic; Panitumumab; Prospective Studies; Pyrrolidines; Randomized Controlled Trials as Topic; Thymine; Trifluridine | 2022 |
Phase 1 study of the safety, pharmacokinetics, and preliminary efficacy of CA102N as monotherapy and in combination with trifluridine-tipiracil in patients with locally advanced or metastatic solid tumors.
Topics: Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Cyclooxygenase 2 Inhibitors; Drug Combinations; Humans; Hyaluronic Acid; Sulfonamides; Trifluridine | 2023 |
Pooled safety analysis from phase III studies of trifluridine/tipiracil in patients with metastatic gastric or gastroesophageal junction cancer and metastatic colorectal cancer.
Topics: Adult; Colonic Neoplasms; Colorectal Neoplasms; Esophagogastric Junction; Frontotemporal Dementia; Humans; Neutropenia; Pyrrolidines; Stomach Neoplasms; Thymine; Trifluridine; Uracil | 2022 |
Trifluridine-tipiracil plus bevacizumab versus capecitabine plus bevacizumab as first-line treatment for patients with metastatic colorectal cancer ineligible for intensive therapy (SOLSTICE): a randomised, open-label phase 3 study.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Capecitabine; Colonic Neoplasms; Colorectal Neoplasms; Female; Humans; Male; Rectal Neoplasms; Trifluridine | 2023 |
Safety and efficacy of trifluridine/tipiracil in previously treated metastatic colorectal cancer: final results from the phase IIIb single-arm PRECONNECT study by duration of therapy.
Topics: Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Drug Combinations; Duration of Therapy; Humans; Trifluridine | 2023 |
Trifluridine/tipiracil+bevacizumab (BEV) vs. fluoropyrimidine-irinotecan+BEV as second-line therapy for metastatic colorectal cancer: a randomised noninferiority trial.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Colonic Neoplasms; Colorectal Neoplasms; Drug Combinations; Frontotemporal Dementia; Humans; Irinotecan; Pyrrolidines; Rectal Neoplasms; Thymine; Trifluridine | 2023 |
Trifluridine-Tipiracil and Bevacizumab in Refractory Metastatic Colorectal Cancer.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Colonic Neoplasms; Colorectal Neoplasms; Drug Combinations; Humans; Pyrrolidines; Rectal Neoplasms; Trifluridine; Uracil | 2023 |
Panitumumab Plus Trifluridine-Tipiracil as Anti-Epidermal Growth Factor Receptor Rechallenge Therapy for Refractory RAS Wild-Type Metastatic Colorectal Cancer: A Phase 2 Randomized Clinical Trial.
Topics: Aged; Antibodies, Monoclonal; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Female; Humans; Male; Panitumumab; Proto-Oncogene Proteins B-raf; Trifluridine | 2023 |
Effects of prior therapies on outcomes with trifluridine/tipiracil in patients with metastatic gastric/gastroesophageal junction cancer in a randomized phase III trial (TAGS).
Topics: Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Drug Combinations; Esophagogastric Junction; Humans; Irinotecan; Paclitaxel; Pyrrolidines; Stomach Neoplasms; Trifluridine | 2023 |
Study protocol of an open-label, single arm phase II trial investigating the efficacy and safety of Trifluridine/Tipiracil combined with irinotecan as a second line therapy in patients with cholangiocarcinoma (TRITICC).
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Bile Duct Neoplasms; Bile Ducts, Intrahepatic; Biliary Tract Neoplasms; Cholangiocarcinoma; Cisplatin; Clinical Trials, Phase II as Topic; Colorectal Neoplasms; Deoxycytidine; Disease Progression; Frontotemporal Dementia; Gemcitabine; Humans; Irinotecan; Prospective Studies; Trifluridine | 2023 |
Bevacizumab, Irinotecan, and Biweekly Trifluridine/Tipiracil for Metastatic Colorectal Cancer: MODURATE, a Phase Ib Study.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Colonic Neoplasms; Colorectal Neoplasms; Drug Combinations; Humans; Irinotecan; Rectal Neoplasms; Trifluridine; Uracil | 2023 |
Phase II Trial of Trifluridine/Tipiracil Plus Irinotecan in Patients with Advanced, Refractory Biliary Tract Carcinoma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Biliary Tract; Carcinoma; Gastrointestinal Neoplasms; Humans; Irinotecan; Trifluridine | 2023 |
Effect of 12-week of aerobic exercise on hormones and lipid profile status in adolescent girls with polycystic ovary syndrome: A study during COVID-19.
Topics: Actin Cytoskeleton; Actins; Adaptor Proteins, Signal Transducing; Adenocarcinoma; Adenosine Triphosphate; Adsorption; Adult; Africa, Eastern; Aged; Air Pollutants; Air Pollution; Air Pollution, Indoor; Alcohol Drinking; Allergens; Alzheimer Disease; Amyotrophic Lateral Sclerosis; Animals; Anti-Bacterial Agents; Antibodies; Antibodies, Immobilized; Antigen Presentation; Antigens, CD; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Antioxidants; Apoptosis; Aptamers, Nucleotide; Asthma; Asthma, Exercise-Induced; Atrophy; Autophagy; Azoospermia; Bacillus cereus; Bacterial Infections; Beclin-1; Bile Duct Neoplasms; Bile Ducts, Intrahepatic; Biofouling; Biological Monitoring; Biomarkers; Biomarkers, Tumor; Biosensing Techniques; Blastocyst; Bone Neoplasms; Bone Regeneration; Bronchoconstriction; Burkitt Lymphoma; C9orf72 Protein; Campylobacter; Campylobacter Infections; Campylobacter jejuni; Carcinogenesis; Carcinoma, Hepatocellular; Carcinoma, Pancreatic Ductal; Carcinoma, Squamous Cell; Cardiomyopathies; Caregivers; Carmine; Case-Control Studies; Catalysis; Cattle; Cause of Death; CCAAT-Enhancer-Binding Protein-alpha; CD8-Positive T-Lymphocytes; Cefepime; Cell Differentiation; Cell Line, Tumor; Cell Nucleus; Cell Transdifferentiation; Chelating Agents; Chemical and Drug Induced Liver Injury, Chronic; Chemoradiotherapy, Adjuvant; Child; Child, Preschool; China; Chlorquinaldol; Cholangiocarcinoma; Cholera; Chromatin; Clinical Trials as Topic; Cognitive Dysfunction; Cohort Studies; Colonic Neoplasms; Colorectal Neoplasms; Colorimetry; Cooking; Coordination Complexes; COVID-19; Creatinine; CRISPR-Cas Systems; Critical Care; Critical Illness; Cross-Sectional Studies; Cryopreservation; Cryoprotective Agents; Cysteine; Cytokines; Device Removal; Diet; Diet, High-Fat; Diet, Mediterranean; Dietary Supplements; Dimethyl Sulfoxide; Dipeptides; Disease Models, Animal; Dithiothreitol; DNA; DNA Repeat Expansion; DNA, Bacterial; DNA, Complementary; Dopamine; Electrochemical Techniques; Electrodes; Endocannabinoids; Environmental Exposure; Environmental Monitoring; Environmental Pollutants; Enzyme-Linked Immunosorbent Assay; Erlotinib Hydrochloride; Escherichia coli; Escherichia coli O157; Esophageal Neoplasms; Esophagitis, Peptic; Ethylene Glycol; Europium; Exanthema; Fallopian Tubes; Feces; Female; Fertilization in Vitro; Fluoresceins; Fluorescent Dyes; Follicle Stimulating Hormone; Follow-Up Studies; Food Microbiology; Forced Expiratory Volume; Forkhead Transcription Factors; Frontotemporal Dementia; G-Quadruplexes; Galactose; Gastroenteritis; Gastrointestinal Diseases; Gastrointestinal Microbiome; Gastrointestinal Neoplasms; Gastrointestinal Tract; Gene Frequency; Genetic Association Studies; Genetic Predisposition to Disease; Genital Neoplasms, Female; Genome-Wide Association Study; Genome, Viral; Genomics; Genotype; Glucose; Glutathione; Glycerol; Gold; Graphite; GTPase-Activating Proteins; Heat-Shock Proteins; Heme Oxygenase-1; Hepacivirus; Hepatitis C; Hepatocytes; Histamine; Histocompatibility Antigens Class II; Hoarseness; Hospice and Palliative Care Nursing; Humans; Hydrogen; Hydrogen Peroxide; Hydrogen Sulfide; Hydroxybenzoates; Hydroxyl Radical; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperthermia, Induced; Hysteroscopy; Immunoassay; Indigo Carmine; Inflammation; Inflammatory Bowel Diseases; Insulin Resistance; Intensive Care Units; Interleukin-11; Interleukin-6; Interleukins; Iodine Radioisotopes; Iran; Iridium; Islets of Langerhans; Kinetics; Lactation; Lactobacillus; Lactobacillus plantarum; Lamins; Latin America; Lead; Lectins; Leukopenia; Ligands; Limit of Detection; Lipopolysaccharides; Lipoprotein Lipase; Liver; Liver Cirrhosis; Liver Neoplasms; Lolium; Luminescent Measurements; Luminol; Lung; Luteinizing Hormone; Macrophages; Magnetic Phenomena; Magnetic Resonance Imaging; Male; Malnutrition; Maltose; Manganese Compounds; Maternal Nutritional Physiological Phenomena; Melatonin; Metabolic Engineering; Metal Nanoparticles; Metallocenes; Metaplasia; Methicillin-Resistant Staphylococcus aureus; Methylation; Mevalonic Acid; Mexico; Mice; Mice, Inbred C57BL; Mice, Transgenic; Microbial Sensitivity Tests; Microbiota; MicroRNAs; Milk; Mitomycin; Molecular Diagnostic Techniques; Molecular Docking Simulation; Monte Carlo Method; Moringa oleifera; Multiple Sclerosis; Muscle Strength; Muscle, Skeletal; Nanocomposites; Nanotubes, Carbon; Neoadjuvant Therapy; Neoplasms; Neurodegenerative Diseases; Neurotransmitter Agents; NF-E2-Related Factor 2; Nickel; Nitrogen Dioxide; Non-alcoholic Fatty Liver Disease; Nucleic Acid Amplification Techniques; Nucleic Acid Hybridization; Nucleocapsid Proteins; Nutritional Status; Obesity; Osteogenesis; Osteosarcoma; Oxidation-Reduction; Oxides; Oxygen; Oxyquinoline; Pain; Palliative Care; Pancreatic Neoplasms; Pandemics; Particulate Matter; Peroxidase; Peroxidases; Phagocytosis; Phaseolus; Photothermal Therapy; Point-of-Care Systems; Polyethyleneimine; Polymers; Polymorphism, Single Nucleotide; Polysomnography; Postoperative Complications; Pregnancy; Pregnant Women; Prenatal Exposure Delayed Effects; Prevalence; Printing, Three-Dimensional; Probability; Probiotics; Prognosis; Prophages; Prospective Studies; Proteomics; Proto-Oncogene Proteins; Pseudomonas aeruginosa; Pseudomonas putida; Pulmonary Disease, Chronic Obstructive; Pulmonary Embolism; Pyridines; Pyrroles; Quality of Life; Quinolones; Rabbits; Rats; Rats, Sprague-Dawley; Reactive Oxygen Species; Real-Time Polymerase Chain Reaction; Receptors, Histamine; Receptors, Histamine H2; Recombinases; Rectal Neoplasms; Reperfusion Injury; Respiration; Respiratory Function Tests; Respiratory Rate; Respiratory Sounds; Retrospective Studies; rho GTP-Binding Proteins; Risk Assessment; Risk Factors; RNA; RNA, Messenger; RNA, Ribosomal, 16S; Robotic Surgical Procedures; Running; Rural Population; Saccharomyces cerevisiae; Salpingectomy; Sarcopenia; SARS-CoV-2; Seeds; Semen; Sensitivity and Specificity; Sepsis; Shock, Septic; Signal Transduction; Silicon Dioxide; Silver; Sirtuin 1; Skin Neoplasms; Sleep Apnea, Obstructive; Soil; Spain; Spectrum Analysis, Raman; Sperm Retrieval; Spermatozoa; Spirometry; Staphylococcus aureus; STAT3 Transcription Factor; Stereoisomerism; Sterilization, Tubal; Stroke Volume; Sulfadiazine; Sulfites; Superoxide Dismutase; Surface Plasmon Resonance; tau Proteins; Testis; Testosterone; Thioredoxin-Disulfide Reductase; Thyroid Neoplasms; Thyroidectomy; Trans-Activators; Transcription Factor AP-1; Treatment Outcome; Triazoles; Triclosan; Trifluridine; Tumor Microenvironment; Tumor Necrosis Factor-alpha; United States; Uracil; Vagina; Vegetables; Ventricular Function, Left; Ventricular Pressure; Vibrio cholerae; Vietnam; Virulence; Vital Capacity; Vitrification; Walking; Water; Water Pollutants, Radioactive; Whole Genome Sequencing; Wind; YAP-Signaling Proteins; Zeolites; Zinc Oxide | 2023 |
Panitumumab plus trifluridine/tipiracil as anti-EGFR rechallenge therapy in patients with refractory RAS wild-type metastatic colorectal cancer: Overall survival and subgroup analysis of the randomized phase II VELO trial.
Topics: Antineoplastic Combined Chemotherapy Protocols; Colonic Neoplasms; Colorectal Neoplasms; Humans; Panitumumab; Rectal Neoplasms; Trifluridine | 2023 |
Randomised phase II trial of trifluridine/tipiracil (FTD/TPI) plus ramucirumab (RAM) versus trifluridine/tipiracil for previously treated patients with advanced gastric or esophagogastric junction adenocarcinoma (RETRIEVE study, WJOG15822G).
Topics: Adenocarcinoma; Adult; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Drug Combinations; Esophagogastric Junction; Frontotemporal Dementia; Humans; Prospective Studies; Ramucirumab; Stomach Neoplasms; Trifluridine; Young Adult | 2023 |
67 other study(ies) available for trifluridine and ma-1
| Article | Year |
|---|---|
An interview with Alfredo Falcone and Lisa Salvatore: RECOURSE and trifluridine/tipiracil in metastatic colorectal cancer.
Topics: Achievement; Antineoplastic Combined Chemotherapy Protocols; Career Choice; Clinical Trials as Topic; Colorectal Neoplasms; Disease Management; Drug Discovery; Humans; Neoplasm Metastasis; Neoplasm Staging; Pyrrolidines; Research; Thymine; Treatment Outcome; Trifluridine | 2016 |
Self-Reported Adherence to Trifluridine and Tipiracil Hydrochloride for Metastatic Colorectal Cancer: A Retrospective Cohort Study.
Topics: Abdominal Pain; Administration, Oral; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Appetite; Colorectal Neoplasms; Female; Humans; Male; Medication Adherence; Middle Aged; Nausea; Neutropenia; Pyrrolidines; Retrospective Studies; Self Report; Thymine; Trifluridine; Vomiting | 2016 |
Effect of a novel oral chemotherapeutic agent containing a combination of trifluridine, tipiracil and the novel triple angiokinase inhibitor nintedanib, on human colorectal cancer xenografts.
Topics: Administration, Oral; Animals; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; HCT116 Cells; HT29 Cells; Humans; Indoles; Inhibitory Concentration 50; Male; Mice, Inbred BALB C; Mice, Nude; Pyrrolidines; Thymine; Trifluridine; Tumor Burden; Xenograft Model Antitumor Assays | 2016 |
[A Case of Metastatic Colorectal Cancer with Brain Metastasis Treated with Combined TFTD and Bevacizumab Therapy].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Brain Neoplasms; Colonic Neoplasms; Female; Humans; Pyrrolidines; Thymine; Trifluridine | 2018 |
Evaluating trifluridine + tipiracil hydrochloride in a fixed combination (TAS-102) for the treatment of colorectal cancer.
Topics: Colorectal Neoplasms; Drug Combinations; Humans; Prognosis; Pyrrolidines; Thymine; Trifluridine; Uracil | 2018 |
Regorafenib or Trifluridine/Tipiracil in Refractory Metastatic Colorectal Cancer? A Perspective on the Basis of Pharmacological Costs.
Topics: Colorectal Neoplasms; Humans; Phenylurea Compounds; Pyridines; Pyrrolidines; Retrospective Studies; Thymine; Trifluridine | 2018 |
Reply to P. Di Nardo et al and R. Sun et al.
Topics: Colonic Neoplasms; Double-Blind Method; Drug Combinations; Humans; Pyrrolidines; Thymine; Trifluridine; Uracil | 2018 |
Interpreting the Benefit of Trifluridine/Tipiracil in Metastatic Colorectal Cancer With Respect to Progression-Free Survival and Overall Survival.
Topics: Colorectal Neoplasms; Double-Blind Method; Drug Combinations; Humans; Progression-Free Survival; Pyrrolidines; Respect; Thymine; Trifluridine; Uracil | 2018 |
Statistical and Clinical Significance in the TERRA Study.
Topics: Double-Blind Method; Drug Combinations; Humans; Pyrrolidines; RNA, Long Noncoding; Telomere; Thymine; Trifluridine; Uracil | 2018 |
Effective Sequential Combined Chemotherapy with Trifluridine/Tipiracil and Regorafenib in Human Colorectal Cancer Cells.
Topics: Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Cell Line, Tumor; Colorectal Neoplasms; Humans; Male; Mice, Nude; Phenylurea Compounds; Pyridines; Pyrrolidines; Thymine; Trifluridine | 2018 |
9 weeks that matter for patients with gastric cancer.
Topics: Double-Blind Method; Gastrectomy; Humans; Pyrrolidines; Stomach Neoplasms; Thymine; Trifluridine | 2018 |
Safety profile of trifluridine/tipiracil monotherapy in clinical practice: results of the German compassionate-use program for patients with metastatic colorectal cancer.
Topics: Aged; Antineoplastic Agents; Colorectal Neoplasms; Compassionate Use Trials; Drug-Related Side Effects and Adverse Reactions; Female; Germany; Humans; Male; Middle Aged; Prospective Studies; Pyrrolidines; Thymine; Trifluridine | 2018 |
Economic evaluation of trifluridine and tipiracil hydrochloride in the treatment of metastatic colorectal cancer in Greece.
Topics: Adult; Antimetabolites; Colorectal Neoplasms; Cost-Benefit Analysis; Greece; Humans; Pyrrolidines; Survival Analysis; Thymine; Trifluridine | 2019 |
Trifluridine/tipiracil in metastatic gastric cancer.
Topics: Double-Blind Method; Drug Combinations; Humans; Pyrrolidines; Stomach Neoplasms; Thymine; Trifluridine | 2019 |
Leukocytoclastic vasculitis with late-onset Henoch-Schönlein purpura after trifluridine/tipiracil treatment.
Topics: Adult; Appendiceal Neoplasms; Fatal Outcome; Glomerulonephritis; Humans; IgA Vasculitis; Kidney Failure, Chronic; Male; Neoplasm Metastasis; Pyrrolidines; Thymine; Trifluridine; Vasculitis, Leukocytoclastic, Cutaneous | 2018 |
Pharmacological effects of the simultaneous and sequential combinations of trifluridine/tipiracil (TAS-102) and 5-fluorouracil in fluoropyrimidine-sensitive colon cancer cells.
Topics: Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Cell Proliferation; Colonic Neoplasms; Drug Combinations; Drug Synergism; Fluorouracil; Humans; Pyrrolidines; Thymine; Trifluridine; Tumor Cells, Cultured | 2020 |
Real-World Adherence in Patients with Metastatic Colorectal Cancer Treated with Trifluridine plus Tipiracil or Regorafenib.
Topics: Antineoplastic Combined Chemotherapy Protocols; Cohort Studies; Colorectal Neoplasms; Drug Combinations; Female; Humans; Longitudinal Studies; Male; Medication Adherence; Middle Aged; Neoplasm Metastasis; Phenylurea Compounds; Pyridines; Pyrrolidines; Retrospective Studies; Thymine; Trifluridine | 2020 |
CD44/CD133-Positive Colorectal Cancer Stem Cells are Sensitive to Trifluridine Exposure.
Topics: AC133 Antigen; Antimetabolites, Antineoplastic; Cell Line, Tumor; Colon; Drug Combinations; Drug Synergism; Fluorouracil; Gene Expression; Humans; Hyaluronan Receptors; Inhibitory Concentration 50; Neoplastic Stem Cells; Pyrrolidines; Spheroids, Cellular; Thymidine Kinase; Thymine; Trifluridine | 2019 |
Should we optimize cytotoxic therapy by dosing to neutropenia? Lessons from TAS-102.
Topics: Colorectal Neoplasms; Drug Combinations; Humans; Neutropenia; Pyrrolidines; Thymine; Trifluridine; Uracil | 2020 |
Neutropenia in metastatic colorectal cancer receiving trifluridine/tipiracil.
Topics: Colorectal Neoplasms; Humans; Neutropenia; Pyrrolidines; Thymine; Trifluridine | 2020 |
Reply to the letter to the editor 'Neutropenia in metastatic colorectal cancer receiving trifluridine/tipiracil' by Colloca et al.
Topics: Colorectal Neoplasms; Humans; Neutropenia; Pyrrolidines; Thymine; Trifluridine | 2020 |
Economic Sustainability of Trifluridine/Tipiracil for the Treatment of Refractory Metastatic Colorectal Cancer in Real Life.
Topics: Colorectal Neoplasms; Cost-Benefit Analysis; Drug Combinations; England; Humans; Pyrrolidines; Thymine; Trifluridine; Uracil; Wales | 2020 |
Trifluridine/tipiracil in earlier lines of chemotherapy for advanced colorectal cancer.
Topics: Bevacizumab; Colorectal Neoplasms; Drug Combinations; Humans; Pyrrolidines; Thymine; Trifluridine | 2020 |
IgA Nephropathy Associated with Trifluridine/Tipiracil: A Case Report.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Colonic Neoplasms; Glomerulonephritis, IGA; Humans; Male; Pyrrolidines; Thymine; Trifluridine | 2020 |
Trifluridine/Tipiracil in heavily pretreated metastatic gastric cancer. A perspective based on pharmacological costs.
Topics: Drug Combinations; Drug Costs; Humans; Neoplasm Metastasis; Pyrrolidines; Stomach Neoplasms; Thymine; Trifluridine | 2020 |
Trifluridine/tipiracil in combination with local therapy may be a favorable option for refractory metastatic colorectal cancer patients: A case report.
Topics: Adenocarcinoma; Aged; Drug Combinations; Humans; Liver Neoplasms; Male; Neoplasm Staging; Peritoneal Neoplasms; Pyrrolidines; Quality of Life; Rectal Neoplasms; Salvage Therapy; Thymine; Trifluridine | 2020 |
Quality of life in a real-world study of patients with metastatic colorectal cancer treated with trifluridine/tipiracil.
Topics: Antineoplastic Agents; Colorectal Neoplasms; Cross-Sectional Studies; Female; Humans; Male; Prospective Studies; Pyrrolidines; Quality of Life; Thymine; Trifluridine | 2020 |
Trifluridine/tipiracil or regorafenib in refractory metastatic colorectal cancer: from clinical trials to daily clinical practice.
Topics: Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Drug Combinations; Humans; Phenylurea Compounds; Pyridines; Pyrrolidines; Thymine; Trifluridine | 2020 |
[Long-Term Survivor with Recurrent Gastric Cancer Using Trifluridine/Tipiracil as a Late-Line Chemotherapy].
Topics: Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Drug Combinations; Humans; Neoplasm Recurrence, Local; Pyrrolidines; Stomach Neoplasms; Survivors; Thymine; Trifluridine; Uracil | 2020 |
Trifluridine/tipiracil plus ramucirumab in gastric cancer.
Topics: Antibodies, Monoclonal, Humanized; Humans; Pyrrolidines; Ramucirumab; Stomach Neoplasms; Thymine; Trifluridine | 2021 |
[A Case of an Elderly Frail Patient with Unresectable Colorectal Cancer Controlled by Trifluridine/Tipiracil with Bevacizumab Therapy as a First-Line Treatment].
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Colorectal Neoplasms; Female; Frail Elderly; Humans; Liver Neoplasms; Pyrrolidines; Thymine; Trifluridine | 2021 |
Mechanism of acquired 5FU resistance and strategy for overcoming 5FU resistance focusing on 5FU metabolism in colon cancer cell lines.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Cell Line, Tumor; Colonic Neoplasms; Drug Resistance, Neoplasm; Drug Screening Assays, Antitumor; Floxuridine; Fluorouracil; Humans; Hydroxyurea; Metabolic Networks and Pathways; Pyrrolidines; Ribonucleotide Reductases; Thymidine Phosphorylase; Thymine; Trifluridine | 2021 |
Cost-effectiveness of trifluridine/tipiracil as a third-line treatment of metastatic gastric cancer, including adenocarcinoma of the gastrohesophageal junction, among patients previously treated in Greece.
Topics: Adenocarcinoma; Colorectal Neoplasms; Cost-Benefit Analysis; Greece; Humans; Pyrrolidines; Quality-Adjusted Life Years; Stomach Neoplasms; Thymine; Trifluridine | 2022 |
Regorafenib-to-trifluridine/tipiracil Versus the Reverse Sequence for Refractory Metastatic Colorectal Cancer Patients: A Multicenter Retrospective Real-life Experience.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Drug Administration Schedule; Female; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Neoplasm Metastasis; Phenylurea Compounds; Progression-Free Survival; Pyridines; Pyrrolidines; Thymine; Trifluridine | 2021 |
Lonsurf (trifluridine/tipiracil): Assessing the impact of dose related toxicities and progression free survival in (refractory) metastatic colorectal cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Colonic Neoplasms; Colorectal Neoplasms; Drug Combinations; Humans; Progression-Free Survival; Rectal Neoplasms; Retrospective Studies; Trifluridine; Uracil | 2022 |
Cost-effectiveness of trifluridine/tipiracil against nivolumab for heavily pretreated metastatic gastric cancer in Japan.
Topics: Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Cost-Benefit Analysis; Drug Combinations; Humans; Japan; Nivolumab; Pyrrolidines; Stomach Neoplasms; Thymine; Trifluridine; Uracil | 2021 |
Trifluridine/tipiracil versus placebo for third or later lines of treatment in metastatic gastric cancer: an exploratory subgroup analysis from the TAGS study.
Topics: Colorectal Neoplasms; Humans; Pyrrolidines; Stomach Neoplasms; Thymine; Trifluridine; Uracil | 2021 |
Long Term Real-World Outcomes of Trifluridine/Tipiracil in Metastatic Colorectal Cancer-A Single UK Centre Experience.
Topics: Colorectal Neoplasms; Drug Combinations; Humans; Pyrrolidines; Retrospective Studies; Thymine; Trifluridine; United Kingdom | 2021 |
Trifluridine/Tipiracil and Regorafenib in Patients with Metastatic Colorectal Cancer: A Retrospective Study at a Tertiary Oncology Center.
Topics: Colorectal Neoplasms; Humans; Longitudinal Studies; Phenylurea Compounds; Pyridines; Pyrrolidines; Retrospective Studies; Thymine; Trifluridine | 2021 |
Standard-Dose Trifluridine/Tipiracil as Safe Treatment Alternative in Metastatic Colorectal Cancer Patients With DPD Deficiency.
Topics: Colonic Neoplasms; Dihydropyrimidine Dehydrogenase Deficiency; Humans; Pyrrolidines; Rectal Neoplasms; Thymine; Trifluridine | 2021 |
Trifluridine/Tipiracil in Metastatic Colorectal Cancer: A UK Multicenter Real-world Analysis on Efficacy, Safety, Predictive and Prognostic Factors.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Humans; Prognosis; Pyrrolidines; Retrospective Studies; Thymine; Trifluridine; Uracil | 2021 |
The Efficacy and Safety of Trifluridine/Tipiracil Treatment for Elderly Patients With Metastatic Colorectal Cancer in a Real-world Setting.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Female; Humans; Male; Progression-Free Survival; Pyrrolidines; Retrospective Studies; Thymine; Trifluridine | 2021 |
Trifluridine/Tipiracil in Combination with Bevacizumab in First-Line for Metastatic Colorectal Cancer: A Way Forward. A Point of View Based on Cost-Effectiveness.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Colonic Neoplasms; Colorectal Neoplasms; Cost-Benefit Analysis; Drug Combinations; Humans; Pyrrolidines; Rectal Neoplasms; Thymine; Trifluridine; Uracil | 2022 |
The effect of prognostic factors at baseline on the efficacy of trifluridine/tipiracil in patients with metastatic colorectal cancer: A Portuguese exploratory analysis.
Topics: Aged; Colonic Neoplasms; Colorectal Neoplasms; Female; Humans; Liver Neoplasms; Male; Portugal; Prognosis; Pyrrolidines; Rectal Neoplasms; Retrospective Studies; Thymine; Trifluridine; Uracil | 2022 |
Sequential Treatment With Trifluridine/Tipiracil and Regorafenib in Refractory Metastatic Colorectal Cancer Patients: An AGEO Prospective "Real-World Study".
Topics: Antineoplastic Combined Chemotherapy Protocols; Colonic Neoplasms; Colorectal Neoplasms; Drug Combinations; Frontotemporal Dementia; Humans; Phenylurea Compounds; Prospective Studies; Pyridines; Pyrrolidines; Rectal Neoplasms; Thymine; Trifluridine; Uracil | 2022 |
Quality of Life and Survival of Metastatic Colorectal Cancer Patients Treated With Trifluridine-Tipiracil (QUALITAS).
Topics: Antineoplastic Combined Chemotherapy Protocols; Colonic Neoplasms; Colorectal Neoplasms; Drug Combinations; Frontotemporal Dementia; Humans; Prospective Studies; Pyrrolidines; Quality of Life; Rectal Neoplasms; Thymine; Trifluridine | 2022 |
Influence of precedent drug on the subsequent therapy in the sequence of trifluridine/tipiracil with/out bevacizumab and regorafenib for unresectable or recurrent colorectal cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Colorectal Neoplasms; Humans; Neoplasm Recurrence, Local; Phenylurea Compounds; Pyridines; Pyrrolidines; Thymine; Trifluridine; Uracil | 2022 |
Long-term survivors of metastatic colorectal cancer treated with trifluridine/tipiracil.
Topics: Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Drug Combinations; Humans; Pyrrolidines; Survivors; Thymine; Trifluridine | 2022 |
Efficacy, safety and prognostic factors in patients with refractory metastatic colorectal cancer treated with trifluridine/tipiracil plus bevacizumab in a real-world setting.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Colonic Neoplasms; Colorectal Neoplasms; Drug Combinations; Humans; Middle Aged; Prognosis; Pyrrolidines; Rectal Neoplasms; Retrospective Studies; Thymine; Trifluridine; Uracil | 2022 |
Real-World Activity and Safety of Trifluridine-Tipiracil Plus Bevacizumab Therapy in Patients with Refractory Metastatic Colorectal Cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Colonic Neoplasms; Colorectal Neoplasms; Female; Humans; Male; Middle Aged; Retrospective Studies; Trifluridine; Uracil | 2022 |
An Exploration of Trifluridine/Tipiracil Monotherapy and in Combination With Bevacizumab or Immune Checkpoint Inhibitors for Patients With Metastatic Colorectal Cancer: A Real-World Study.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Colonic Neoplasms; Colorectal Neoplasms; Drug Combinations; Drug-Related Side Effects and Adverse Reactions; Humans; Immune Checkpoint Inhibitors; Rectal Neoplasms; Trifluridine; Uracil | 2023 |
Evaluation of a Novel Combination Therapy, Based on Trifluridine/Tipiracil and Fruquintinib, against Colorectal Cancer.
Topics: Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Drug Combinations; Frontotemporal Dementia; Humans; Mice; Trifluridine; Vascular Endothelial Growth Factor A | 2023 |
Trifluridine/Tipiracil in the Real-World Management of Metastatic Gastric and Gastroesophageal Junction Cancers in Canada.
Topics: Adult; Aged; Canada; Colorectal Neoplasms; Esophageal Neoplasms; Esophagogastric Junction; Frontotemporal Dementia; Humans; Stomach Neoplasms; Trifluridine; Uracil | 2022 |
Regorafenib is suitable for advanced colorectal cancer patients who have previously received trifluridine/tipiracil plus bevacizumab.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Colorectal Neoplasms; Drug Combinations; Female; Humans; Male; Middle Aged; Phenylurea Compounds; Pyrrolidines; Retrospective Studies; Thymine; Trifluridine; Uracil | 2023 |
A Real-World Comparison of Regorafenib and Trifluridine/Tipiracil in Refractory Metastatic Colorectal Cancer in the United States.
Topics: Antineoplastic Combined Chemotherapy Protocols; Colonic Neoplasms; Colorectal Neoplasms; Drug Combinations; Humans; Phenylurea Compounds; Prospective Studies; Rectal Neoplasms; Trifluridine; United States; Uracil | 2023 |
Clinical Significance of Neutrophil-to-Lymphocyte Ratio/Serum Albumin Ratio in Patients With Metastatic Gastric or Gastroesophageal Junction Cancer Administered Trifluridine/Tipiracil.
Topics: Clinical Relevance; Esophagogastric Junction; Frontotemporal Dementia; Humans; Lymphocytes; Neutrophils; Prognosis; Retrospective Studies; Serum Albumin; Stomach Neoplasms; Trifluridine | 2023 |
Emetogenicity and Risk Factors of Nausea and Vomiting in Patients With Metastatic Colorectal Cancer Receiving Trifluridine/Tipiracil and Bevacizumab Chemotherapy.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Colonic Neoplasms; Colorectal Neoplasms; Drug Combinations; Humans; Nausea; Rectal Neoplasms; Risk Factors; Trifluridine; Uracil; Vomiting | 2023 |
Evaluation of Irinotecan and Trifluridine/Tipiracil as Fourth-line Treatments After Third-line Nivolumab for Advanced Gastric Cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Drug Combinations; Frontotemporal Dementia; Humans; Irinotecan; Nivolumab; Stomach Neoplasms; Trifluridine; Uracil | 2023 |
Effectiveness, safety and quality of life of trifluridine/tipiracil in pretreated patients with metastatic colorectal cancer: Real-world data from the noninterventional TACTIC study in Germany.
Topics: Antineoplastic Combined Chemotherapy Protocols; Colonic Neoplasms; Colorectal Neoplasms; Drug Combinations; Frontotemporal Dementia; Humans; Prospective Studies; Pyrrolidines; Quality of Life; Rectal Neoplasms; Trifluridine; Uracil | 2023 |
Analysis of neutropenia as a predictive factor of the efficacy of trifluridine-tipiracil treatment.
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Colonic Neoplasms; Colorectal Neoplasms; Drug Combinations; Humans; Middle Aged; Neutropenia; Prospective Studies; Pyrrolidines; Retrospective Studies; Trifluridine | 2023 |
Prognostic factors in refractory metastatic colorectal cancer patients treated with Trifluridine/Tipiracil.
Topics: Antineoplastic Combined Chemotherapy Protocols; Colonic Neoplasms; Colorectal Neoplasms; Drug Combinations; Humans; Neoplasm Recurrence, Local; Prognosis; Pyrrolidines; Rectal Neoplasms; Retrospective Studies; Trifluridine; Uracil | 2023 |
Third-Line Therapy in Metastatic Colorectal Cancer.
Topics: Bevacizumab; Colorectal Neoplasms; Humans; Trifluridine | 2023 |
Third-Line Therapy in Metastatic Colorectal Cancer. Reply.
Topics: Bevacizumab; Colorectal Neoplasms; Humans; Trifluridine | 2023 |
The REWRITE Study - REal-WoRld effectIveness of TrifluridinE/tipiracil in Patients with Previously Treated Metastatic Colorectal Cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Colonic Neoplasms; Colorectal Neoplasms; Drug Combinations; Humans; Middle Aged; Rectal Neoplasms; Trifluridine; Uracil | 2023 |
Real-world evidence of trifluridine/tipiracil plus bevacizumab in metastatic colorectal cancer using an administrative claims database in Japan.
Topics: Bevacizumab; Colonic Neoplasms; Colorectal Neoplasms; Frontotemporal Dementia; Humans; Japan; Retrospective Studies; Trifluridine; Uracil | 2023 |
Efficacy and safety of trifluridine/tipiracil plus ramucirumab in comparison with trifluridine/tipiracil monotherapy for patients with advanced gastric cancer-single institutional experience.
Topics: Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Drug Combinations; Humans; Ramucirumab; Retrospective Studies; Stomach Neoplasms; Trifluridine; Uracil | 2023 |
Renal impairment as a risk factor for trifluridine/tipiracil-induced adverse events in metastatic colorectal cancer patients from the REGOTAS study.
Topics: Antineoplastic Combined Chemotherapy Protocols; Colonic Neoplasms; Colorectal Neoplasms; Drug Combinations; Frontotemporal Dementia; Humans; Neutropenia; Pyrrolidines; Rectal Neoplasms; Retrospective Studies; Risk Factors; Thymine; Trifluridine; Uracil | 2023 |